Peptide Antigen Identification Using IgG Proxies for Heart Failure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying antigen specificity in T cell responses during non-autoimmune diseases like heart failure are costly, technically challenging, and limited in applicability, and there is a need for effective therapeutic and diagnostic approaches to prevent or manage these diseases.
Innovation Solution
A method using IgG-switched antibodies as a proxy for T cell antigen specificity, involving a microarray assay with peptide antigens to identify relevant peptides driving T cell responses in non-autoimmune diseases, followed by database querying for homologous human proteins, and utilizing these peptides for diagnostic and therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods are used to identify antigen specificity in T cell responses, then diagnostic accuracy can be achieved, but the process becomes costly and technically challenging
Solution Approach 1:
The patent uses IgG-switched antibodies as an intermediary to indirectly identify T cell antigen specificity. Instead of directly analyzing T cell responses which are technically complex, the method captures T cell responses through B cell-produced antibodies that have undergone class switching to IgG, providing a simpler proxy measurement that maintains diagnostic accuracy
Solution Approach 2:
The method creates a copy of T cell antigen specificity information through IgG antibodies. The IgG-bound peptide profile serves as a copy or surrogate representation of T cell responses, allowing identification of antigen specificity without directly manipulating or analyzing T cells themselves
2Measurement precision
If current methods are used to identify antigen specificity in T cell responses, then diagnostic accuracy can be achieved, but the cost increases significantly
Solution Approach 1:
By using IgG antibodies as a mediator, the method converts a expensive and complex T cell analysis into a more economical antibody-based assay. The IgG-switched antibodies serve as a cost-effective proxy that preserves the essential diagnostic information about T cell antigen specificity
Solution Approach 2:
The method employs a peptide microarray with synthesized peptides that can be produced cost-effectively. These peptide arrays serve as disposable or reusable platforms that are significantly cheaper than maintaining complex T cell culture and analysis systems
3Measurement precision
If current methods are used to identify antigen specificity, then some diagnostic information can be obtained, but applicability is limited
Solution Approach 1:
The IgG-based approach provides a universal method that can be applied across different diseases and antigen types. The peptide microarray can be configured with disease-relevant peptides, making the same basic assay platform applicable to multiple conditions including heart failure, cancer, and autoimmune diseases
Solution Approach 2:
The method allows flexible modification of assay parameters including the peptide sequences included on the microarray, the disease model organisms used, and the specific IgG populations analyzed. This adaptability enables the same core methodology to be tuned for different diagnostic applications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables accurate diagnosis and potential prevention of non-autoimmune diseases by identifying peptide antigens that induce or mediate disease progression, providing diagnostic markers and therapeutic targets for conditions such as heart failure.
Implementation Method 1
contacting a first biological fluid sample containing IgG immunoglobulins from a first non-human animal affected by the non-autoimmune disease with a microarray comprising a plurality of isolated or synthesized peptide antigens... detecting the binding of one or more of the IgG immunoglobulins present in the first sample with one or more of the peptide antigens in the microarray
Data Source
Figure 1A~1C
Figure 2
Figure 3
AI summary
The invention provides a new method for identifying peptide antigens relevant to a non- autoimmune disease involving T cell activation as well as novel peptides identified therefrom. The isolated peptides of the invention are useful in the diagnosis, prevention and/or treatment of a cardiovascular disease, more specifically heart failure (HF). The invention further provides a pharmaceutical composition comprising at least one isolated peptide of the invention and a pharmaceutically acceptable carrier, vehicle, excipient and/or diluent. The pharmaceutical composition of the invention is suitable to be orally administered as a tolerizing vaccine.